Shorter radiation treatment followed by surgery for soft tissue sarcomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the use of neoadjuvant hypofractionated radiotherapy followed by surgical resection in patients with soft tissue sarcomas. Participants will receive either ultra-hypofractionated radiotherapy over 5 days or moderately hypofractionated radiotherapy over 15 days, aiming to reduce the overall treatment duration compared to traditional methods. The study will assess the efficacy of these approaches in achieving local control of the disease and evaluate the side effects and complication rates associated with the treatments. Patients will be monitored for a minimum of two years post-treatment to gather comprehensive data on outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
* ECOG performance status 0-2
* Patient must be deemed able to comply with radiation treatment and surgery

Exclusion Criteria:

* History of prior radiation to the same area to be irradiated
* Pregnancy
* Active collagen vascular disease or patients genetically predisposed to increased radiation related side effects

Where it's running

• Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Eric Shinohara, MD — Vanderbilt Medical Center
• Study coordinator: Vanderbilt-Ingram Service for Timely Access
• Email: cip@vumc.org
• Phone: 800-811-8480

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Pazopanib added to a multi-drug regimen for kids and young adults with recurrent soft tissue sarcomas

  This study tests whether adding pazopanib to a regimen of trabectedin, ipilimumab, and nivolumab is safe and possibly beneficial for children and young adults with recurrent soft tissue sarcomas.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07444619

• Combining immune therapy with chemotherapy for advanced soft tissue sarcoma

  This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06849986

• Evaluating the CINSARC biomarker in soft-tissue sarcomas and chemotherapy effectiveness

  This study is testing if a specific genetic marker can help predict how well chemotherapy will work for patients with non-metastatic soft-tissue sarcomas.

  Recruiting at 7 sites Institut Bergonié · Bordeaux and 9 other locations · NCT02789384

• Using 68Ga-grazytracer PET to monitor immunotherapy responses in advanced soft tissue sarcomas

  This study is testing if a special type of imaging can help doctors see how well immunotherapy is working for people with advanced soft tissue sarcomas.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06644287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.